Aditxt, Inc. has announced a significant milestone for its target acquisition, Appili Therapeutics Inc., with the U.S. Food and Drug Administration (FDA) providing positive feedback on the development strategy for ATI-1801, Appili's topical antiparasitic product. This alignment with the FDA is a crucial step toward the New Drug Application (NDA) submission.
Development of ATI-1801
ATI-1801 is being developed as a topical antiparasitic treatment. Appili Therapeutics is strategically focused on identifying and developing novel therapies for urgent infections with unmet needs. The company's pipeline includes an FDA-approved metronidazole suspension, a vaccine candidate against biological weapons, and the ATI-1801 topical antiparasitic.
Strategic Implications for Aditxt
Aditxt's interest in Appili Therapeutics is part of a broader strategy to expand its portfolio of health innovations. Aditxt is also pursuing a merger agreement with Evofem Biosciences, Inc. The closing of the acquisition of Appili is subject to several conditions, including approval by target shareholders and Aditxt raising sufficient capital.
About Appili Therapeutics Inc.
Appili Therapeutics is dedicated to solving life-threatening infections. The company focuses on systematically identifying urgent infections with unmet needs and strategically developing a pipeline of novel therapies to prevent deaths and improve lives.
